MERRIMACK PHARMACEUTICALS IN's ticker is MACK and the CUSIP is 590328209. A total of 63 filers reported holding MERRIMACK PHARMACEUTICALS IN in Q2 2023. The put-call ratio across all filers is 0.21 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $450,980 | +111.0% | 29,807 | +106.0% | 0.00% | – |
| Q1 2024 | $213,737 | -54.7% | 14,471 | -58.9% | 0.00% | – |
| Q4 2023 | $471,992 | +9.5% | 35,197 | +0.7% | 0.00% | – |
| Q3 2023 | $430,971 | +147.8% | 34,953 | +147.2% | 0.00% | – |
| Q2 2023 | $173,947 | -59.4% | 14,142 | -59.5% | 0.00% | – |
| Q1 2023 | $428,896 | +164.6% | 34,898 | +146.8% | 0.00% | – |
| Q4 2022 | $162,067 | +192836.9% | 14,142 | 0.0% | 0.00% | – |
| Q2 2022 | $84 | -100.0% | 14,142 | -46.5% | 0.00% | – |
| Q1 2019 | $184,000 | +80.4% | 26,414 | -0.3% | 0.00% | – |
| Q4 2018 | $102,000 | -73.6% | 26,495 | -63.5% | 0.00% | – |
| Q3 2018 | $387,000 | -42.2% | 72,684 | -46.7% | 0.00% | – |
| Q2 2018 | $669,000 | +188.4% | 136,241 | +372.3% | 0.00% | – |
| Q1 2018 | $232,000 | -41.4% | 28,846 | -25.4% | 0.00% | – |
| Q4 2017 | $396,000 | -75.0% | 38,678 | -64.5% | 0.00% | – |
| Q3 2017 | $1,585,000 | – | 109,025 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Rise Advisors, LLC | 272 | $4,108 | 0.00% |
| DIMENSIONAL FUND ADVISORS LP | 318,995 | $4,826,394 | 0.00% |
| Covestor Ltd | 106 | $0 | 0.00% |
| Farther Finance Advisors, LLC | 77 | $0 | 0.00% |
| JBF Capital, Inc. | 39,637 | $1,189 | 0.00% |
| GOLDMAN SACHS GROUP INC | 29,807 | $450,980 | 0.00% |
| NISA INVESTMENT ADVISORS, LLC | 15 | $0 | 0.00% |
| CWM, LLC | 22 | $0 | 0.00% |
| CALDWELL SUTTER CAPITAL, INC. | 7,458 | $0 | 0.00% |
| RHUMBLINE ADVISERS | 2,480 | $37,519 | 0.00% |